Gilead Sciences (Brazil) Top Management

GILD34 Stock  BRL 287.56  4.47  1.58%   
Gilead Sciences employs about 31 people. The company is managed by 9 executives with a total tenure of roughly 16 years, averaging almost 1.0 years of service per executive, having 3.44 employees per reported executive. Analysis of Gilead Sciences' management performance can provide insight into the company performance.
Daniel ODay  Chairman
Chairman of the Board, CEO
Andrew Dickinson  President
Executive Vice President - Corporate Development and Strategy
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.

Gilead Sciences Management Team Effectiveness

The company has return on total asset (ROA) of 0.1045 % which means that it generated a profit of $0.1045 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.216 %, meaning that it generated $0.216 on every $100 dollars invested by stockholders. Gilead Sciences' management efficiency ratios could be used to measure how well Gilead Sciences manages its routine affairs as well as how well it operates its assets and liabilities.

Gilead Sciences Workforce Comparison

Gilead Sciences is rated # 5 in number of employees category among its peers. The total workforce of Drug Manufacturers - Major industry is currently estimated at about 9,783. Gilead Sciences adds roughly 31.0 in number of employees claiming only tiny portion of equities under Drug Manufacturers - Major industry.
The company has Profit Margin (PM) of 0.17 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.4 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.4.

Gilead Sciences Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Gilead Sciences Price Series Summation is a cross summation of Gilead Sciences price series and its benchmark/peer.

Gilead Sciences Notable Stakeholders

A Gilead Sciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Gilead Sciences often face trade-offs trying to please all of them. Gilead Sciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Gilead Sciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Daniel ODayChairman of the Board, CEOProfile
Andrew DickinsonExecutive Vice President - Corporate Development and StrategyProfile
Johanna MercierChief Commercial OfficerProfile
Deborah TelmanGen AffairsProfile
Jyoti MehraEx HRProfile
Jacquie CFAVP RelationsProfile
Diane WilfongCorp VPProfile
Michael QuigleyVP BiologyProfile
Linda HigginsVP InnovationProfile

About Gilead Sciences Management Performance

The success or failure of an entity such as Gilead Sciences often depends on how effective the management is. Gilead Sciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Gilead management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Gilead management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. GILEAD DRN operates under Drug Manufacturers - Major classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 11000 people.
Please note, the presentation of Gilead Sciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Gilead Sciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Gilead Sciences' management manipulating its earnings.

Gilead Sciences Workforce Analysis

Traditionally, organizations such as Gilead Sciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Gilead Sciences within its industry.

Gilead Sciences Manpower Efficiency

Return on Gilead Sciences Manpower

Revenue Per Employee880M
Revenue Per Executive3B
Net Income Per Employee148.1M
Net Income Per Executive510.2M

Complementary Tools for Gilead Stock analysis

When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
CEOs Directory
Screen CEOs from public companies around the world
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities